1. Inhibition of 2-arachydonoylgycerol degradation attenuates orofacial neuropathic pain in trigeminal nerve-injured mice
- Author
-
Shumpei Unno, Kojiro Takahashi, Hiroshi Ando, Masanori Otake, Mohammad Zakir Hossain, Rantaro Kamimura, Yuji Masuda, Isao Saito, and Junichi Kitagawa
- Subjects
Male ,0301 basic medicine ,Stimulation ,Arachidonic Acids ,Pharmacology ,Glycerides ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Facial Pain ,Animals ,Medicine ,Benzodioxoles ,Enzyme Inhibitors ,General Dentistry ,JZL184 ,Trigeminal nerve ,Behavior, Animal ,business.industry ,Endocannabinoid system ,Monoacylglycerol Lipases ,Mice, Inbred C57BL ,Monoacylglycerol lipase ,030104 developmental biology ,chemistry ,Neuropathic pain ,Upper cervical spinal cord ,Neuralgia ,Trigeminal Nerve Injuries ,business ,030217 neurology & neurosurgery ,Endocannabinoids ,Enzymatic degradation - Abstract
Current therapeutics are not effective for orofacial neuropathic pain, and better options are needed. The present study used inferior orbital nerve (ION)-injured mice to investigate the effect of inhibiting monoacylglycerol lipase (MAGL), an enzyme that degrades the major endocannabinoid 2-arachydonoylgycerol (2-AG) in orofacial neuropathic pain. The head-withdrawal threshold to mechanical stimulation of the whisker pad was reduced on days 3, 5, and 7 after ION injury. Injection of JZL184, a selective inhibitor of MAGL, on day 7 after ION injury attenuated the reduction in head-withdrawal threshold at 2 h after administration. Moreover, the numbers of MAGL-immunoreactive neurons in the trigeminal subnucleus caudalis (Vc) and upper cervical spinal cord (C1-C2) were significantly greater in ION-injured mice than in sham-operated mice but were reduced after administration of JZL184. The increase in MAGL immunoreactivity suggests that increased 2-AG production is followed by rapid enzymatic degradation of 2-AG. JZL184 inhibited this degradation and thus increased 2-AG concentration in the brain, particularly in the Vc and C1-C2 regions, thus attenuating pain. Our findings suggest that inhibition of 2-AG degradation by MAGL inhibitors is a promising therapeutic option for treatment of orofacial neuropathic pain.
- Published
- 2018
- Full Text
- View/download PDF